Ji Xing takes Biogen’s clinical stroke candidate off pause

12 Jan 2024
firstwordpharma.com
License out/inPhase 2
Ji Xing Pharmaceuticals acquired global rights to Biogen’s acute ischaemic stroke treatment on Friday, following a pause in its development last year.
The Chinese drug developer, which is mostly focused on cardiovascular diseases, will pay undisclosed upfront and milestone payments for BIIB131, a small molecule plasminogen activator designed to break down blood clots and inhibit local inflammation at the site of thrombosis. Biogen has said this combination could allow for an extended treatment window compared to existing thrombolytic agents
However, last April, Biogen decided to pause the initiation of a Phase IIb study of BIIB131 as part of a wider pipeline trim. The company paid $22 million for an option and subsequent licensing of BIIB131 from Japanese drugmaker TMS in 2021.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.